According to Times of India, Novartis obtained favourable court orders restraining five Ahmedabad-based pharma companies from manufacturing its patented drug for diabetes, Vildagliptin. Further, citing validity of its patent till 09 December 2019, Novartis moved the commercial court in Vadodara to ensure that four other companies do not get into production of the drug. It is reported that Novartis approached the Court after obtaining the requisite information from the State Government.
More from my site
Novartis succeeds in 37 patent infringement lawsuits related to Vidagliptin – Judge Tyagi dismisses the 38th lawsuit for lack of evidence
SpicyIP Fellowship 2017-18: Del HC Upholds Interim Injunction Against Sale of Cipla’s Copy of Novartis’ Respiratory Drug ‘Onbrez’- Cipla Withdraws Revocation Plea for Novartis’ Onbrez Patents, Informs DIPP in an RTI Reply
USTR urged to clarify position on compulsory licensing of generic medicines
Guest Post: Novartis and Myriad: A Surprisingly Similar Tale of Access to Medicine and limits on Patent Eligibility
Supreme Court rejects bid by Novartis to patent Glivec
2 comments.
Am I missing something, or is “aggressive patent strategy” being used to mean “enforcing its patent”? Seems a bit much.
Kind of agree with you, Mr. Sadly No.
However, I believe that the bent was more in the context of patent expiring in 15 months from now … I am sure Novartis is (rightly so) going to not let any non-licensed player before Dec 2019.